Mariya Marusova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mariya Marusova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anna A. Kostareva
Almazov National Medical Research Centre
3 shared publications - Mariya Bortsova
Almazov National Medical Research Center
3 shared publications - Sofiya Andreeva
Almazov National Medical Research Centre
3 shared publications - A. A. Streltsova
Almazov National Medical Research Centre
2 shared publications - Alexander G. Bobylev
Scientific Center of Genetics and Life Sciences, Sirius University of Science and Technology, Sirius 354340, Russia
2 shared publications - Alexandra Ya. Gudkova
Pavlov University ; Almazov National Medical Research Centre
2 shared publications
Latest Publications
- Open Access
- 17 December 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (12) , 499
Genetic Spectrum, Clinical Characteristics, and Molecular Pathogenesis of Hypertrophic Cardiomyopathy Requiring Heart Transplantation
Hypertrophic cardiomyopathy (HCM) progressing to end-stage heart failure and heart transplantation (HT) is a rare clinical scenario with an insufficiently explored genetic background. In this single-center retrospective cohort study, we aimed to characterize the genetic spectrum, variants of HCM adverse remodeling, and aspects of molecular pathogenesis of this subgroup. The study included 14 patients (9 females), among whom 10 developed a dilated/hypokinetic phenotype and 4 a restrictive phenotype. In 13 patients (93%), at least one pathogenic or likely pathogenic genetic variant was identified. Dilated remodeling/hypokinesis was associated with loss-of-function variants in LAMP2 (3) in females, ALPK3homo (1), MYH7 (1), MYBPC3 (1), a heterozygous missense variant in TRIM63 (1), FLNCtv (1), TTNtv (2). For the latter two, electrophoretic analysis of titin isoform composition and protein content in myocardial fragments from explanted hearts confirmed the functional significance of TTN gene variants. The restrictive phenotype in the adult group was associated with carriage of multiple pathogenic sarcomere gene variants: MYL3homo (1), MYBPC3+TPM1 (1), an MYH7 converter domain variant (1), and, in one child, with a TNNT2 variant. This findings support HCM progressing to HT is characterized by a higher frequency of variants in non-sarcomeric genes and Danon disease compared to the general HCM cohort.
- 17 December 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (12) , 499
Open AccessGenetic Spectrum, Clinical Characteristics, and Molecular Pathogenesis of Hypertrophic Cardiomyopathy Requiring Heart Transplantation
Hypertrophic cardiomyopathy (HCM) progressing to end-stage heart failure and heart transplantation (HT) is a rare clinical scenario with an insufficiently explored genetic background. In this single-center retrospective cohort study, we aimed to characterize the genetic spectrum, variants of HCM adverse remodeling, and aspects of molecular pathogenesis of this subgroup. The study included 14 patients (9 females), among whom 10 developed a dilated/hypokinetic phenotype and 4 a restrictive phenotype. In 13 patients (93%), at least one pathogenic or likely pathogenic genetic variant was identified. Dilated remodeling/hypokinesis was associated with loss-of-function variants in LAMP2 (3) in females, ALPK3homo (1), MYH7 (1), MYBPC3 (1), a heterozygous missense variant in TRIM63 (1), FLNCtv (1), TTNtv (2). For the latter two, electrophoretic analysis of titin isoform composition and protein content in myocardial fragments from explanted hearts confirmed the functional significance of TTN gene variants. The restrictive phenotype in the adult group was associated with carriage of multiple pathogenic sarcomere gene variants: MYL3homo (1), MYBPC3+TPM1 (1), an MYH7 converter domain variant (1), and, in one child, with a TNNT2 variant. This findings support HCM progressing to HT is characterized by a higher frequency of variants in non-sarcomeric genes and Danon disease compared to the general HCM cohort.
- Open Access
- 2 October 2025
- Published by MDPI AG in Preprints.org
Genetic Spectrum, Clinical Characteristics, and Molecular Pathogenesis of Hypertrophic Cardiomyopathy Requiring Heart Transplantation
Hypertrophic cardiomyopathy (HCM) progressing to end-stage heart failure and heart transplantation (HT) is a rare clinical scenario with insufficiently explored genetic background. In this single-center retrospective cohort study we aimed to characterize the genetic spectrum, variants of HCM adverse remodeling, and aspects of molecular pathogenesis of this subgroup. The study included 14 patients (9 females), among whom 10 developed a dilated/hypokinetic phenotype and 4 a restrictive phenotype. In 13 pa-tients (93%), at least one pathogenic or likely pathogenic genetic variant was identified. Dilated remodeling/hypokinesis was associated with loss-of-function variants in LAMP2 (3) in females, ALPK3homo (1), MYH7 (1), MYBPC3 (1), heterozygous missense variant in TRIM63 (1), FLNCtv (1), TTNtv (2). For the latter two electrophoretic analysis of titin isoform composition and protein content in myocardial fragments from ex-planted hearts confirmed the functional significance of TTN gene variants. The restric-tive phenotype in the adult group was associated with carriage of multiple pathogenic sarcomere gene variants: MYL3homo (1), MYBPC3+TPM1 (1), a MYH7 converter domain variant (1), and in 1 child, with a TNNT2 variant. This fundings supports HCM pro-gressing to HT is characterized by a higher frequency of variants in non-sarcomeric genes and Danon disease compared to the general HCM cohort.
- 2 October 2025
- Published by MDPI AG in Preprints.org
Open AccessGenetic Spectrum, Clinical Characteristics, and Molecular Pathogenesis of Hypertrophic Cardiomyopathy Requiring Heart Transplantation
Hypertrophic cardiomyopathy (HCM) progressing to end-stage heart failure and heart transplantation (HT) is a rare clinical scenario with insufficiently explored genetic background. In this single-center retrospective cohort study we aimed to characterize the genetic spectrum, variants of HCM adverse remodeling, and aspects of molecular pathogenesis of this subgroup. The study included 14 patients (9 females), among whom 10 developed a dilated/hypokinetic phenotype and 4 a restrictive phenotype. In 13 pa-tients (93%), at least one pathogenic or likely pathogenic genetic variant was identified. Dilated remodeling/hypokinesis was associated with loss-of-function variants in LAMP2 (3) in females, ALPK3homo (1), MYH7 (1), MYBPC3 (1), heterozygous missense variant in TRIM63 (1), FLNCtv (1), TTNtv (2). For the latter two electrophoretic analysis of titin isoform composition and protein content in myocardial fragments from ex-planted hearts confirmed the functional significance of TTN gene variants. The restric-tive phenotype in the adult group was associated with carriage of multiple pathogenic sarcomere gene variants: MYL3homo (1), MYBPC3+TPM1 (1), a MYH7 converter domain variant (1), and in 1 child, with a TNNT2 variant. This fundings supports HCM pro-gressing to HT is characterized by a higher frequency of variants in non-sarcomeric genes and Danon disease compared to the general HCM cohort.
- Open Access
- 10 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (10S) , 6146
Familial hypertrophic cardiomyopathy with midventricular obstruction associated with MYH7, FHOD3 and BAG3 gene variants: a case report
Introduction. Hypertrophic cardiomyopathy (HCM) with midventricular obstruction (MVO) represents a subgroup of increased risk of adverse outcomes. It contributes to development of apical aneurysm, which is an anatomical substrate for the development of malignant arrhythmias, thromboembolism, as well as progression to end stage systolic heart failure. Genetic causes of HCM with MVO are poorly described in Russian and foreign literature.Brief description. We present a case of a 54-year-old female patient with a familial HCM with isolated MVO and rare missense variants in the MYH7, FHOD3 and BAG3 genes. The clinical performance was represented by a paroxysmal atrial fibrillation, as well as episodes of nonsustained ventricular tachycardia.Discussion. According to the European HCM Risk-sudden cardiac death (SCD) calculator, the patient was stratified into an intermediate risk group. However, we also took into account gadolinium-enhanced myocardial areas according to magnetic resonance imaging, as well as no conditions for MVO surgery. This was key in determining the indications for a cardioverter-defibrillator implantation within primary SCD prevention.
- 10 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (10S) , 6146
Open AccessFamilial hypertrophic cardiomyopathy with midventricular obstruction associated with MYH7, FHOD3 and BAG3 gene variants: a case report
Introduction. Hypertrophic cardiomyopathy (HCM) with midventricular obstruction (MVO) represents a subgroup of increased risk of adverse outcomes. It contributes to development of apical aneurysm, which is an anatomical substrate for the development of malignant arrhythmias, thromboembolism, as well as progression to end stage systolic heart failure. Genetic causes of HCM with MVO are poorly described in Russian and foreign literature.Brief description. We present a case of a 54-year-old female patient with a familial HCM with isolated MVO and rare missense variants in the MYH7, FHOD3 and BAG3 genes. The clinical performance was represented by a paroxysmal atrial fibrillation, as well as episodes of nonsustained ventricular tachycardia.Discussion. According to the European HCM Risk-sudden cardiac death (SCD) calculator, the patient was stratified into an intermediate risk group. However, we also took into account gadolinium-enhanced myocardial areas according to magnetic resonance imaging, as well as no conditions for MVO surgery. This was key in determining the indications for a cardioverter-defibrillator implantation within primary SCD prevention.